EMHA and Allergan. Elena Ruiz de la Torre, Executive Director of EMHA attended a business meeting on 23 January with the Allergan Company. The purpose of the meeting was to share ideas and priorities to explore areas of collaboration and identify opportunities between EMHA and Allergan. We also took the opportunity to share the […]
European survey on migraine at work. Analysis of results and conclusions. The objective of this study is to know the situation of migraine workers within the workplace and compare the situation in the different participating countries. The objective of this study is to know the situation of migraine workers within the workplace and compare the
Each year, September 12th is the European Migraine Day of Action. Today, EMHA’s President and Executive Director have been invited by MEP Esteban Gonzalez Pons and MEP Dolors Montserrat to the European Parliament to discuss about how to better help the affected ones to give light to the disease and how to improve the life
European Migraine Day of Action with MEPS in the European Parliament Read More »
Elena Ruiz de la Torre, presented at the IHC the movement #LightToMigraine, an initiative to
mobilize and activate the Affected Migraine community and show how extraordinary they are.
The Dawn of a New Era in Migraine Awareness Read More »
Nancy Baum Lipsitz remembers the night the pain began. She’d had a glass of white wine with a friend and went to bed with a terrible headache. The next day, she still felt horrible, the beginning of what she called a “rolling tide” of near constant migraines and lower level headaches. For three years she
New drugs, decades in the making, are providing relief for migraines. Read More »
Eli Lilly announces that the European Commission (EC) has approved the commercialization of galcanezumab ( Emgality ) as a prophylactic treatment of migraine in adults suffering from at least four days of migraine per month . Galcanezumab is a humanized monoclonal antibody that binds to the peptide related to the calcite gene (CGRP, for its acronym in English) associated with episodes
“Green light” to Lilly’s monoclonal antibody to migraine Read More »
AEMICE together with Universidad de Sevilla (Seville University) and Novartis and a scientific committee of expert neurologists has created the Migraine Atlas by AEMICE 2018 which reflects the real situation of the 4.5 million people who suffer from migraine in Spain! Unlike other studies “Migraine Atlas” includes the patients and also their families perspective about their condition,
Migraine Atlas by AEMICE Read More »
We would like to give the warmest and biggest congratulations to our Board Officer and Cluster Headache Delegate, Kalina Tyminski!!! We are beyond proud to announce that Mrs. Tyminski just received a Certificate of Commendation for Young Volunteer Advocate from the EFNA Advocacy Awards 2018. Thank you for all your hard work, dedication, outstanding contribution
Congratulations Kalina!! Read More »
Copenhagen University is now offering a Master on Headache Disorders. It´s a continuing professional development programme for healthcare professionals. The programme of the Master on Headache Disorders requires a minimum of 6 individual visits to Copenhagen, Denmark over a two-year period: Modules 1 to 4 are organized with an e-learning self-study period followed by one week
Master on Headache Disorders Read More »
Migraine Awareness Week 2018 MAI held an accredited Health Care Professional Seminar, during which two international speakers presented on Migraine: Diagnosis and Treatment, and the Development of the new Anti-CGRP medication. Prof. Lars Edvinsson and Prof. Allan Purdy, both members of the IHS, followed this up by doing a webinar for members of the Irish
Migraine Association of Ireland Read More »
Don't miss out on any updates! Join our community and discover
the latest research, treatments, and events on migraine.
Subscribe now!
